Search results
Results from the WOW.Com Content Network
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced a summary of its actions to improve its capital position, including the recently announced private repurchases of senior secured convertible ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary ...
Intercept Pharmaceuticals' Ocaliva is approved for PBC patients in combination with ursodeoxycholic acid (UDCA), or as a monotherapy in patients unable to tolerate UDCA. Iqirvo is also to be used ...
The biotech turned in another strong quarterly performance with rising sales for Ocaliva and a regulatory filing for a new indication on the way.
What: Shares of Intercept Pharmaceuticals , a. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail. Sign in ...
The rejection marks Intercept's second failed attempt at securing approval for the drug to treat patients with non-alcoholic steatohepatitis (NASH) - a liver disease that affects 5% of U.S. adults ...
For premium support please call: 800-290-4726 more ways to reach us
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Today, the ...